Publication Date:
2018-09-29
Description:
Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma Methylation of all 〈i〉BRCA1〈/i〉 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma, Published online: 28 September 2018; doi:10.1038/s41467-018-05564-z Around 10% of high-grade serous ovarian carcinomas (HGSOC) harbor BRCA1 promoter methylation, but it is uncertain how it predicts response to PARP inhibition. Here, the authors show that homozygous BRCA1 methylation predicts response to rucaparib while heterozygous methylation of BRCA1 predicts resistance in HGSOC.
Electronic ISSN:
2041-1723
Topics:
Biology
,
Chemistry and Pharmacology
,
Natural Sciences in General
,
Physics
Permalink